Three FDA inspectors examined the site’s quality management systems and manufacturing processes during the week-long audit. This approval reinforces the company’s regulatory track record, maintaining their 100% pass rate for FDA Pre-License Inspections. The facility is equipped with twelve 4,000L single-use bioreactors, allowing for flexible production scales between 4,000L and 20,000L. Beyond manufacturing capacity, the plant integrates digital platforms and rooftop photovoltaic systems designed to reduce carbon output and improve resource efficiency.

CEO Dr. Chris Chen noted that the successful inspection validates the company's sustained investment in global quality standards. As of the end of 2025, WuXi Biologics had navigated 46 regulatory inspections from bodies including the FDA and EMA, securing 136 facility license approvals. The organization currently manages a global network of 25 drug substance and 18 drug product facilities, supporting nearly 1,000 integrated client projects.